Unregistered Semaglutide Tirzepatide recall: SAHPRA & SAPC seize products at Sentra Pharmacy

On 11 May 2026, the South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC) conducted a joint inspection at Sentra Pharmacy in Silverton, Pretoria. This operation uncovered the unlawful manufacturing and distribution of unregistered GLP‑1/GIP injectable medicines, including Semaglutide, Tirzepatide, and their combination formulations.

Key findings of the inspection

The inspection revealed several regulatory breaches, including:

• Illegal importation of active pharmaceutical ingredients (APIs) such as Semaglutide and Tirzepatide.
• Lack of analytical testing for identity, potency, and purity of the products.
• Inadequate sterile and aseptic manufacturing conditions, posing a high risk of contamination.
• Absence of a pharmacovigilance system, despite reports of adverse events, including hospitalisations.
• Illegal advertising and promotional activities targeting healthcare professionals and consumers.

Enforcement actions

SAHPRA and SAPC have taken decisive action to protect public health:

• All GLP‑1/GIP finished products at the facility were seized.
• Sentra Pharmacy was ordered to initiate a full recall of distributed products.
• Regulatory, disciplinary, and legal actions are being pursued, including potential removal from the pharmacy register for involved professionals.

Public safety alert

SAHPRA and SAPC urge the public to consult healthcare professionals for weight management or diabetes treatment. Consumers are advised to report any adverse reactions or suspicious products to SAHPRA.

Dr Boitumelo Semete‑Makokotlela, CEO of SAHPRA, stated: “The unlawful manufacture and distribution of unregistered medicines pose significant health risks. SAHPRA will continue to act decisively to protect public health.”

Vincent Tlala, CEO of SAPC, added: “Unlawful manufacturing, promotion and distribution of unregistered GLP-1 medicines for weight loss is a serious violation of the law and a direct threat to public safety. Following the inspection conducted at Sentra Pharmacy, the SAPC will pursue decisive regulatory action against those involved. Pharmacists and pharmacy support personnel found selling, compounding or distributing these unregistered medicines risk severe disciplinary action. Including possible removal from the register. Council will not tolerate any conduct that compromises patient safety or the integrity of the pharmacy profession.”